GET THE APP

Translational research in pancreatic cancer: The experience of Pe | 8262
Pancreatic Disorders & Therapy

Pancreatic Disorders & Therapy
Open Access

ISSN: 2165-7092

+44 1478 350008

Translational research in pancreatic cancer: The experience of Peking Union Medical College Hospital


International Conference on Pancreatic Disorders and Treatment

October 17-19, 2016 Chicago, USA

Junchao Guo

Peking Union Medical College Hospital, China

Posters & Accepted Abstracts: Pancreat Disord Ther

Abstract :

As the key department of Peking Union Medical College Hospital (PUMCH), translational research of pancreatic cancer (PanC) in the center of pancreatic surgery is a long traditional department in PUMCH and was established in 1950��?s by Prof. Xianjiu Zeng. It published the first scientific paper in pancreatology in China and enjoys the best prestige in the fields of pancreatic endocrine and exocrine tumor in China. In 2010, we established the first pancreatic consultation center in PUMCH to carry out multidisciplinary treatment (MDT). There were 9 GI-related clinical departments with strong faculty support. 22 eminent professors and specialists were involved. Up to now, more than 100 joint consultations have been held, and 700 cases of patients gained benefits. Our research targets of prevention and control measures of pancreatic cancer are based on three levels: 1. etiologic factors; 2. early diagnosis and treatment; 3. comprehensive therapy. Seven research projects are undergoing in our center, including: 1. Building national biological specimen bank and data center; 2. Creating three pancreatic cancer progression models; 3. Formulating reliable methods in early diagnosis of pancreatic cancer; 4. Exploring the mechanism of chemotherapy resistance; 5. Investigating tumor specific SNVs by exon sequencing; 6. Establishing a pancreatic cancer treatment network in China. 7. Searching the protein net of pancreatic cancer. From 2002 to 2012, our center got 45 research projects supported by Chinese government and the research funding was close to 50 million Yuan. Up to now, we have collected 1,916 cases of PanC samples and 9,975 cases of other biologic samples of PanC. It is the first time to discover five cancer related miRNA (hsa-let-7c, hsa-miR-122-5p, hsa-miR-451a, hsa-miR-142-5p, and hsa-miR-199a- 3p) by our center which may be useful for early diagnosis of PanC, and to build the largest animal model data of PanC in the world. The achievements we have got include: one experts consensus; two sample libraries; two patient information data libraries; three technology platforms; 164 article; five patents; three books; thirty five research projects and 129 students.

Biography :

Email: gjcpumch@163.com

Top